First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related ...

Q1 2026 earnings call: revenue and guidance, Casgevy royalties, DTx/SeQure growth drivers, and $10M buyback—read key takeaways.

A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at About MaxCyte At MaxCyte ®, we are committed to building better cells together. As a ...

MaxCyte: Building the Future of Cell and Gene Therapy Innovation MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue ...

Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks MaxCyte ( (MXCT)) has provided an ...

ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance ...

MaxCyte (NASDAQ:MXCT) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement. Analysts anticipate MaxCyte to report an ...

Gaithersburg-based MaxCyte Inc., a provider of platform technologies for cell engineering, announced Monday the commencement of an underwritten offering of 12 million shares of common stock at an ...

MaxCyte Inc MXCT shares plummeted after the company released preliminary Q3 revenue of $7.8 million – 8.0 million, a Y/Y decrease of 25 -27%, due to continued reduced customer activity in the sector.

Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund" Q1 2026 Investor ...